Chronic infantile neurologic cutaneous and articular syndrome

Lore & Background

The disease is caused in 60% of cases by a mutation in the CIAS1 gene, which helps control inflammation. Mutations in this gene also cause familial cold urticaria and Muckle–Wells syndrome. In many patients, the mutation is not inherited from parents, indicating a sporadic genetic change. The diagnosis is based on observing the constellation of symptoms and signs, with blood tests showing signs of long-standing inflammation. Genetic testing for CIAS1/NLRP3 mutations is now a standard diagnostic tool and is considered a specific test for confirming the diagnosis.

Reader's Guide

Chronic infantile neurologic cutaneous and articular syndrome (CINCA) is significant as a model for understanding autoinflammatory diseases, particularly the cryopyrin-associated periodic syndromes. Its identification linked a single gene (CIAS1/NLRP3) to multiple syndromes with overlapping features, highlighting the role of the inflammasome in uncontrolled inflammation. The syndrome's severity—with neonatal onset, progressive neurologic damage, and risk of amyloidosis—underscores the need for early diagnosis. Treatment with anakinra, an interleukin-1 inhibitor, has shown success, offering a targeted approach. The condition's rarity (less than 1 in a million live births) and the fact that most cases are sporadic emphasize the challenge of diagnosis and the importance of genetic testing. Its legacy includes advancing knowledge of interleukin-1-mediated inflammation and paving the way for therapies that have improved outcomes for patients with related syndromes.

Did You Know?

• The syndrome is also known as Prieur–Griscelli syndrome, first described by these authors in 1981.
• About 100 cases have been reported worldwide, with an incidence estimated at less than 1 in a million live births.
• The drug anakinra has been successfully used to treat NOMID.
• In 60% of cases, the disease is caused by a mutation in the CIAS1 gene, which also causes familial cold urticaria and Muckle–Wells syndrome.

The Wolf's Bite: Naming and Nature of the Disease

Systemic lupus erythematosus carries a name that dates back to the thirteenth century, when physicians observed the characteristic facial rash and likened it to the mark left by a wolf's teeth. The Latin word for wolf, lupus, stuck, and the disease has worn that identity for nearly eight hundred years. At its core, SLE is an autoimmune condition: the body's own defense machinery turns against healthy tissue in multiple organs simultaneously. What makes it particularly treacherous is its unpredictability. Patients experience waves of illness, called flares, interspersed with stretches of relative calm known as remission. The clinical picture shifts from person to person and even from week to week within the same individual. Because of this protean behavior, SLE has earned the nickname "the great imitator," a label reflecting how readily its symptoms masquerade as entirely different illnesses. In children under eighteen, the disease tends to strike with greater severity, a variant termed childhood-onset systemic lupus erythematosus. The breadth of possible presentations means that no single symptom defines the condition, and no single organ system is safe from its reach.

A Body Under Siege: Multi-System Manifestations

SLE's reach extends across nearly every organ system, and the pattern of involvement differs markedly between men and women. On the skin, up to seventy percent of patients develop visible lesions, ranging from thick scaly patches of discoid lupus to the well-known butterfly-shaped malar rash that appears in roughly thirty to sixty percent of cases. Joint and muscle pain affects more than ninety percent of those living with the disease, typically striking the small joints of the hands and wrists; however, unlike rheumatoid arthritis, lupus-related arthritis rarely causes permanent structural damage, with fewer than ten percent developing hand or foot deformities. In the blood, anemia appears in about half of pediatric cases, while low platelet and white cell counts can stem from the disease itself or from treatment. The heart is not spared: inflammation of the pericardium, myocardium, or valves, known as Libman-Sacks endocarditis, can all occur, and atherosclerosis progresses faster than in the general population. Women tend to experience more relapses, arthritis, and psychiatric symptoms, whereas men are more prone to seizures, kidney disease, and peripheral neuropathy.

The Elusive Diagnosis: Genetics, Triggers, and the Immune Misfire

Pinpointing exactly why SLE develops in one person and not another remains an open question. The prevailing understanding holds that a blend of inherited susceptibility and environmental triggers sets the stage. Among identical twins, if one twin develops the disease, the other faces a twenty-four percent chance of following the same path, a figure that signals genetics matter but are far from deterministic. Female sex hormones, prolonged sun exposure, cigarette smoking, vitamin D deficiency, and certain infections all appear to nudge risk upward. The actual mechanism involves the immune system producing autoantibodies, most commonly anti-nuclear antibodies, that attack the body's own tissues and trigger widespread inflammation. Diagnosis is notoriously difficult because the hallmark symptoms, fever, fatigue, and joint aches, overlap with countless other conditions. Clinicians must piece together a picture from a constellation of signs and laboratory findings, and some patients endure years of unexplained symptoms before a definitive label is applied. Related but distinct entities, including discoid lupus, neonatal lupus, and subacute cutaneous lupus, further complicate the diagnostic landscape.

Managing Without a Cure: Treatment, Risk, and Who Is Affected

No cure exists for SLE, and management relies on a toolkit of symptomatic and experimental therapies. Nonsteroidal anti-inflammatory drugs, corticosteroids, immunosuppressants, hydroxychloroquine, and methotrexate form the backbone of treatment. Corticosteroids deliver rapid relief but carry a heavy burden of side effects with prolonged use, while alternative medicine has failed to demonstrate any meaningful impact on the disease course. The prognosis is sobering: cardiovascular disease is the leading cause of death among SLE patients, and men who develop the condition face higher mortality than women. Globally, prevalence ranges from twenty to seventy cases per hundred thousand people, with women of childbearing age affected roughly nine times more often than men. The disease most commonly emerges between ages fifteen and forty-five, though it can appear at virtually any age. People of African, Caribbean, and Chinese descent carry a higher risk than those of European heritage, and data from the developing world remain sparse. For women who do become pregnant, the condition elevates obstetric risk, yet the majority of these pregnancies still reach successful term.